Efficacy of the long-acting nitro vasodilator pentaerithrityl tetranitrate in patients with chronic stable angina pectoris receiving anti-anginal background therapy with beta-blockers: A 12-week, randomized, double-blind, placebo-controlled trial

European Heart Journal

Volumn 35, Issue 14, 2014, Pages 895-903

  Münzel, Thomas ^a   Meinertz, Thomas ^b   Tebbe, Ulrich ^c   Schneider, Heinrich Theodor ^d   Stalleicken, Dirk ^e   Wargenau, Manfred ^f   Gori, Tommaso ^a   Klingmann, Ingrid ^g  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c KLINIKUM LIPPE DETMOLD   (Germany)

^d UNIVERSITY OF BONN   (Germany)

^e ALBSTADT SIGMARINGEN UNIVERSITY   (Germany)

^f MARCO GmbH and Co KG   (Germany)

^g Pharmaplex Bvba ^*  (Belgium)

Author keywords

Chronic stable angina; Organic nitrate; Pentaerithrityl tetranitrate; Total exercise duration

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IVABRADINE; PENTAERYTHRITYL TETRANITRATE; PLACEBO; DELAYED RELEASE FORMULATION; VASODILATOR AGENT;

ADULT; ARTICLE; CHRONIC DISEASE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EXERCISE; FEMALE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STABLE ANGINA PECTORIS; TREADMILL EXERCISE; ANGINA, STABLE; CLINICAL TRIAL; DELAYED RELEASE FORMULATION; DRUG EFFECTS; EXERCISE TEST; EXERCISE TOLERANCE; MEDICATION COMPLIANCE; PHASE 3 CLINICAL TRIAL; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; ANGINA, STABLE; CHRONIC DISEASE; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; EXERCISE TEST; EXERCISE TOLERANCE; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PENTAERYTHRITOL TETRANITRATE; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 84898837438     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/eht384     Document Type: Article

References (32)

1. Fox K, Garcia MA, Ardissino D, Buszman P, Camici PG, Crea F, Daly C, De Backer G, Hjemdahl P, Lopez-Sendon J, Marco J, Morais J, Pepper J, Sechtem U, Simoons M, Thygesen K, Priori SG, Blanc JJ, Budaj A, Camm J, Dean V, Deckers J, Dickstein K, Lekakis J, McGregor K, Metra M, Osterspey A, Tamargo J, Zamorano JL. Guidelines on the managementofstable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J 2006;27:1341-1381.
2. Munzel T, Daiber A, Gori T. Nitrate therapy: new aspects concerning molecular action and tolerance. Circulation 2011;123:2132-2144.
3. Elkayam U, Kulick D, McIntosh N, Roth A, Hsueh W, Rahimtoola SH. Incidence of early tolerance to hemodynamic effects of continuous infusion of nitroglycerin in patients with coronary artery disease and heart failure. Circulation 1987;76:577-584.
4. Nyberg G. Current status of isosorbide-5-mononitrate therapy in chronic stable angina pectoris. Am J Ther 1994;1:93-101.
5. Elkayam U, Roth A, Mehra A, Ostrzega E, Shotan A, Kulick D, Jamison M, Johnston JV, Rahimtoola SH. Randomized study to evaluate the relation between oral isosorbide dinitrate dosing interval and the development of early tolerance to its effect on left ventricular filling pressure in patients with chronic heart failure. Circulation 1991;84: 2040-2048.
6. Sekiya M, Sato M, Funada J, Ohtani T, Akutsu H, Watanabe K. Effects of the long-term administration of nicorandil on vascular endothelial function and the progression of arteriosclerosis. J Cardiovasc Pharmacol 2005;46:63-67.
7. Thomas GR, DiFabio JM, Gori T, Parker JD. Once daily therapy with isosorbide-5-mononitrate causes endothelial dysfunction in humans: evidence of a free-radical-mediated mechanism. J Am Coll Cardiol 2007;49:1289-1295.
8. Gori T, Burstein JM, Ahmed S, Miner SE, Al-Hesayen A, Kelly S, Parker JD. Folic acid prevents nitroglycerin-induced nitric oxide synthase dysfunction and nitrate tolerance: a human in vivo study. Circulation 2001;104:1119-1123.
9. Schnorbus B, Schiewe R, Ostad MA, Medler C, Wachtlin D, Wenzel P, Daiber A, Munzel T, Warnholtz A. Effects of pentaerythritol tetranitrate on endothelial function in coronary artery disease: results of the PENTA study. Clin Res Cardiol 2011;99: 115-124.
10. Schuhmacher S, Oelze M, Bollmann F, Kleinert H, Otto C, Heeren T, Steven S, Hausding M, Knorr M, Pautz A, Reifenberg K, Schulz E, Gori T, Wenzel P, Munzel T, Daiber A. Vascular dysfunction in experimental diabetes is improved by pentaerithrityl tetranitrate but not isosorbide-5-mononitrate therapy. Diabetes 2011;60:2608-2616.
11. Thum T, Wiebking V, Ertl G, Bauersachs J. Organic nitrates differentially modulate circulating endothelial progenitor cells and endothelial function in patients with symptomatic coronary artery disease. Antioxid Redox Signal 2012;15:925-931.
12. Gori T, Dragoni S, Di Stolfo G, Sicuro S, Liuni A, Luca MC, Thomas G, Oelze M, Daiber A, Parker JD. Tolerance to nitroglycerin-induced preconditioning of the endothelium: a human in vivo study. Am J Physiol Heart Circ Physiol 2009;298: H340-H345.
13. Dragoni S, Gori T, Lisi M, Di Stolfo G, Pautz A, Kleinert H, Parker JD. Pentaerythrityl tetranitrate and nitroglycerin, but not isosorbide mononitrate, prevent endothelial dysfunction induced by ischemia and reperfusion. Arterioscler Thromb Vasc Biol 2007; 27:1955-1959.
14. McInnis KJ, Balady GJ, Weiner DA, Ryan TJ. Comparison of ischemic and physiologic responses during exercise tests in men using the standard and modified Bruce protocols. Am J Cardiol 1992;69:84-89.
15. Gibbons RJ, Balady GJ, Bricker JT, Chaitman BR, Fletcher GF, Froelicher VF, Mark DB, McCallister BD, Mooss AN, O'Reilly MG, Winters WL, Antman EM, Alpert JS, Faxon DP, Fuster V, Gregoratos G, Hiratzka LF, Jacobs AK, Russell RO, Smith SC. ACC/AHA 2002 guideline update for exercise testing: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). J Am Coll Cardiol 2002;40:1531-1540.
16. Qaseem A, Fihn SD, Dallas P, Williams S, Owens DK, Shekelle P. Management of stable ischemic heart disease: summary of a clinical practice guideline from the American College of Physicians/American College of Cardiology Foundation/American Heart Association/American Association for Thoracic Surgery/Preventive Cardiovascular Nurses Association/Society of Thoracic Surgeons. Ann Intern Med 2012;157:735-743.
17. Bundesärztekammer (BÄ K), Kassenärztliche Bundesvereinigung (KBV), Arbeitsge-meinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Chronische KHK-Langfassung, Modul Medika-mentöse Therapie, 2. Auflage. Version 1.1 (07/2012).
18. DeMots H, Glasser SP. Intermittent transdermal nitroglycerin therapy in the treatment of chronic stable angina. J Am Coll Cardiol 1989;13:786-795.
19. Parker JD, Farrell B, Fenton T, Cohanim M, Parker JO. Counter-regulatory responses to continuous and intermittent therapy with nitroglycerin. Circulation 1991;84: 2336-2345.
20. Parker JD, Parker AB, Farrell B, Parker JO. Intermittent transdermal nitroglycerin therapy. Decreased anginal threshold during the nitrate-free interval. Circulation 1995;91:973-978.
21. Parker JO, Amies MH, Hawkinson RW, Heilman JM, Hougham AJ, Vollmer MC, Wilson RR. Intermittent transdermal nitroglycerin therapy in angina pectoris. Clinically effective without tolerance or rebound. Minitran Efficacy Study Group. Circulation 1995;91:1368-1374.
22. Pepine CJ, Lopez LM, Bell DM, Handberg-Thurmond EM, Marks RG, McGorray S. Effects of intermittent transdermal nitroglycerin on occurrence of ischemia after patch removal: results of the Second Transdermal Intermittent Dosing Evaluation Study (TIDES-II). J Am Coll Cardiol 1997;30:955-961.
23. Ferratini M, Pirelli S, Merlini P, Silva P, Pollavini G. Intermittent transdermal nitrogly-cerin monotherapy in stable exercise-induced angina: a comparison with a continuous schedule. Eur Heart J 1989;10:998-1002.
24. Wenzel P, Oelze M, Coldewey M, Hortmann M, Seeling A, Hink U, Mollnau H, Stalleicken D, Weiner H, Lehmann J, Li H, Forstermann U, Munzel T, Daiber A. Heme oxygenase-1: a novel key player in the development of tolerance in response to organic nitrates. Arterioscler Thromb Vasc Biol 2007;27:1729-1735.
25. Jurt U, Gori T, Ravandi A, Babaei S, Zeman P, Parker JD. Differential effects of pen-taerythritol tetranitrate and nitroglycerin on the development of tolerance and evidence of lipid peroxidation: a human in vivo study. J Am Coll Cardiol 2001;38: 854-859.
26. Giles TD, Iteld BJ, Quiroz AC, Mautner RK. The prolonged effect of pentaerythritol tetranitrate on exercise capacity in stable effort angina pectoris. Chest 1981;80: 142-145.
27. Arce-Gomez E, Aspe y Rosas J, Alcocer Diaz Barreiro L, Diaz Barreiro AL. Antian-ginal effects of pentaerythritol tetranitrate. Nouv Presse Med 1980;9(34 Suppl.): 2487-2491.
28. Tardif JC, Ponikowski P, Kahan T. Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. Eur Heart J 2009;30:540-548.
29. Chaitman BR, Pepine CJ, Parker JO, Skopal J, Chumakova G, Kuch J, Wang W, Skettino SL, Wolff AA. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA 2004;291:309-316.
30. Fox KM, Mulcahy D, Findlay I, Ford I, Dargie HJ. The Total Ischaemic Burden European Trial (TIBET). Effects of atenolol, nifedipine SR and their combination on the exercise test and the total ischaemic burden in 608 patients with stable angina. The TIBET Study Group. Eur Heart J 1996;17:96-103.
31. Knight CJ, Fox KM. Amlodipine versus diltiazem as additional antianginal treatment to atenolol. Centralised European Studies in Angina Research (CESAR) Investigators. Am J Cardiol 1998;81:133-136.
32. Pehrsson SK, Ringqvist I, Ekdahl S, Karlson BW, Ulvenstam G, Persson S. Monother-apy with amlodipine or atenolol versus their combination in stable angina pectoris. Clin Cardiol 2000;23:763-770.